Evidence map›Paper›PMID 40792015›Full record

ArticleBlood neoplasia2025

Treatment discontinuation due to toxicity for patients with acute myeloid leukemia receiving intensive chemotherapy.

Suravi Raychaudhuri, Megan Othus, Mary-Elizabeth M Percival, Guillermo Garcia-Manero, Frederick R Appelbaum, Harry P Erba, Jacob S Appelbaum

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood neoplasia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Suravi RaychaudhuriDivision of Hematology and Oncology, Department of Medicine, University of Washington, Seattle, WA.
Megan OthusClinical Research Division, Fred Hutch Cancer Center, Seattle, WA.
Mary-Elizabeth M PercivalDivision of Hematology and Oncology, Department of Medicine, University of Washington, Seattle, WA.
Guillermo Garcia-ManeroDepartment of Leukemia, MD Anderson Cancer Center, Houston, TX.
Frederick R AppelbaumDivision of Hematology and Oncology, Department of Medicine, University of Washington, Seattle, WA.
Harry P ErbaDivision of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC.
Jacob S AppelbaumDivision of Hematology and Oncology, Department of Medicine, University of Washington, Seattle, WA.

Funding

SWOG Statistics & Data Management Center complex - extension supplement for GY06U10CA180819 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Michael L. LeBlanc · 2014 to 2026
$115.2M
RESEARCH TRAINING IN HEMATOLOGYT32HL007093 · NHLBI · UNIVERSITY OF WASHINGTON · PI Janis L Abkowitz · 1985 to 2026
$13.9M
NCI NIH HHS U10 CA180819NHLBI NIH HHS T32 HL007093
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID40792015
PMCPMC12335950

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.